Attovia Therapeutics: CFO Chan Steven received 140,000 shares

What happened

• Chan Steven, chief financial officer, received a grant of 140,000 derivative securities (award) on Aug 4, 2026 at $0.00 per share, total reported value $0.

Key details

• Transaction date and price: Aug 4, 2026 — grant of 140,000 shares at $0.00 per share (code A, derivative).
• Shares owned after the transaction: filing states no changes are being reported with respect to the reporting person’s beneficial ownership.
• Vesting: 25% of the options vest on Aug 4, 2027; the remaining options vest in equal monthly installments over the following 36 months, subject to continued service (footnote F1).
• Filing status: this is an amendment filed Oct 8, 2026 that amends the Form 4 filed on Aug 6, 2026 and replaces the original filing in its entirety.

Why it may matter

• This filing reports a grant of derivative securities (an award), not a market purchase or sale.
• A filing does not show why the insider traded or why the company acted.